// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

A PHASE 2 STUDY OF THE LSD1 INHIBITOR IMG-7289 (BOMEDEMSTAT) FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA (ET)

Francesca Palandri - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Essential thrombocythemia

N/A

INDIRECT TREATMENT COMPARISONS OF FEDRATINIB VERSUS NAVITOCLAX PLUS RUXOLITINIB: EFFECT ON SPLEEN VOLUME AND SYMPTOMS IN RUXOLITINIB-EXPOSED MYELOFIBROSIS PATIENTS

Pranav Abraham - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Myelofibrosis

Ruxolitinib phosphate

QUIZARTINIB PROLONGED SURVIVAL VS PLACEBO PLUS INTENSIVE INDUCTION AND CONSOLIDATION THERAPY FOLLOWED BY SINGLE-AGENT CONTINUATION IN PATIENTS AGED 18-75 YEARS WITH NEWLY DIAGNOSED FLT3-ITD+ AML

Harry Erba - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Daunorubicin

CARTITUDE-2 COHORT B: UPDATED CLINICAL DATA AND BIOLOGICAL CORRELATIVE ANALYSES OF CILTACABTAGENE AUTOLEUCEL IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY

Mounzer E. Agha - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cytokine release syndrome

N/A

WEEKLY OPPOSED TO BI-WEEKLY BORTEZOMIB AS PART OF INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA IS BETTER TOLERATED AND EQUALLY EFFICIENT: REAL-WORLD DATA FROM A RETROSPECTIVE AUDIT

Lucy Faulkner - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Bortezomib

CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)

Carmelo Carlo-Stella - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Hodgkin's Lymphoma

ADCT301

MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY

Matthew Matasar - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Cytokine release syndrome

N/A

CHRONIC COMPLICATIONS IN THE EAST LONDON SICKLE NEWBORN COHORT STUDY (ELSNCS)

Cynthia Sangarappillai - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

BRUIN CLL-322: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB+VENETOCLAX AND RITUXIMAB VS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CLL/SLL (TRIAL IN PROGRESS)

Anthony R. Mato - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Venetoclax

TECLISTAMAB COMPARED WITH REAL-WORLD THERAPIES IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA

Amrita Krishnan - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Techniclone TNT

LESSONS FROM HIV- HAEMOPHILIA CRISIS AND CURRICULAR LEARNING IN POST COVID TIMES

Mallika Sekhar - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

THERAPEUTIC GENE EDITING OF T CELLS CORRECTS CTLA4 INSUFFICIENCY.

Thomas Fox - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

INVESTIGATING GPR56 FUNCTION IN HUMAN IPSC-DERIVED HEMATOPOIETIC CELLS USING A TET-ON MODEL OF CONSTITUTIVE ACTIVATION

Lorna Mackintosh - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Doxycycline

BONE MINERAL DENSITY REMAINS STABLE IN PYRUVATE KINASE DEFICIENCY PATIENTS RECEIVING LONG-TERM TREATMENT WITH MITAPIVAT

Hanny Al-Samkari - European Hematology Association (EHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Pyruvate kinase (PK) deficiency

N/A

THE FIRST REAL-LIFE MULTICENTRE, INTERNATIONAL, PROSPECTIVE VALIDATION STUDY OF THE ELECTRONIC CHROMOENDOSCOPY SCORING SYSTEM (PICASSO-THE PADDINGTON INTERNATIONAL VIRTUAL CHROMOENDOSCOPY SCORE) AND ITS OUTCOME IN ULCERATIVE COLITIS PATIENTS

Marietta Iacucci - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

RAMAN SPECTROSCOPY CAN DIFFERENTIATE MUCOSAL HEALING FROM NON-HEALING IN INFLAMMATORY BOWEL DISEASE

Samuel C. Smith - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

ENDOSCOPIC RESECTION OF COLON DYSPLASIA IN INFLAMMATORY BOWEL DISEASE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS ON CANCER INCIDENCE AND SAFETY

Babu P. Mohan - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Ophthalmology (OP)

Inflammatory bowel disease

N/A

WIDE AREA TRANSEPITHELIAL SAMPLE ESOPHAGEAL BIOPSY COMBINED WITH COMPUTER ASSISTED 3-DIMENSIONAL TISSUE ANALYSIS (WATS3D) FOR DETECTION OF HIGH GRADE DYSPLASIA AND ADENOCARCINOMA IN BARRETT: EUROPEAN MULTI-CENTER, PROSPECTIVE, RANDOMIZED, TANDEM STUDY.

Raf Bisschops - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade dysplasia

N/A

THE CURRENT DIAGNOSTIC ACCURACY AND INTER-OBSERVER AGREEMENT OF VISUAL IMPRESSION WITH DIGITAL SINGLE-OPERATOR CHOLANGIOSCOPY FOR THE DIAGNOSIS OF INDETERMINATE BILIARY STRICTURES

Pauline M. Stassen - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

OPTIMIZATION OF SURVEILLANCE INTERVALS AFTER SUCCESSFUL RADIOFREQUENCY ABLATION THERAPY FOR DYSPLASTIC BARRETT'S ESOPHAGUS: RESULTS OF AN INTERNATIONAL MULTICENTER COHORT STUDY

Allon Kahn - Digestive Disease Week (DDW) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

High grade dysplasia

N/A

Copyright © 2026. QuantiNova All rights reserved